ERBB2 and invasive breast carcinoma: In daily clinic, HER-2 overexpression (IHC 3+ or FISH+) is only present in a minority of patients with primary invasive breast cancer, although a higher incidence of HER-2-positivity is seen in MBC (26,3% in stage IV versus 15% in stage I-III patients) [23].